Exelixis (EXEL) Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline Mar 8, 2021 08:07AM
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline Mar 8, 2021 08:00AM
Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation Dec 2, 2020 06:00AM
WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA Feb 27, 2019 08:33PM
WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership Feb 11, 2019 07:00PM